Background. The hollow fiber system model of tuberculosis (HFS-TB), in tandem with Monte Carlo experiments, represents a drug development tool (DDT) with the potential for use to develop tuberculosis treatment regimens. However, the predictive accuracy of the HFS-TB, or any other nonclinical DDT such as an animal model, has yet to be robustly evaluated.
One of the pressing problems of modern drug development is the high attrition rate, whereby at most 11% of molecules reach the market; even then, a large percentage is withdrawn for safety reasons. This is costly and prohibitory, especially for antibiotics such as antituberculous drugs, which have a narrow profit margin. Thus, many drug developers have exited this space. Even for those pharmaceutical companies brave enough to see antibiotic drug development to the end, the doses are in several cases not optimized, leading to predictable development of multidrug resistance [1] . A potential solution is to identify preclinical models that are predictive of how well an antibiotic will perform in the clinic, based on principles of pharmacokinetics-pharmacodynamics (PK/PD) [2] [3] [4] . Starting in 2003, the hollow fiber system model of tuberculosis (HFS-TB) has been studied for such purposes [5] . In addition, a mathematically defensible pathway to translate the preclinical findings to optimal clinical dose, optimal drug concentration exposures, and proportion of patients expected to respond to therapy, is vital. Monte Carlo experiments of pharmacometric models have been used for this purpose [6] [7] [8] . The predictive accuracy of the HFS-TB in tandem with Monte Carlo simulations, or indeed the predictive accuracy of any nonclinical drug development tool (DDT) used for any chemotherapy, has not been quantified. Here, we present a formal examination of the predictive accuracy of the HFS-TB.
The word "prediction" is via the Latin praedicere, which is "to say before" the event. Following, we define prediction in pharmacology as making a set of assertions at a time t 1 , which are then examined for veracity at time t 2 when clinical results are eventually known. Thus, the condition is that t 2 > t 1 . To avoid Vaticinium ex eventu ( prophecy written after the fact), or "hindsight bias," we expand the differences in time of prediction to time of clinical study publication to t 2 > t 1 + 6 months. Moreover, for a DDT, we assert as important that the prediction at t 1 has to be quantitative. Thus, it is not enough to say that drug x will be efficacious, but instead to say drug y at dose x will result in efficacy in a specified percentage of patients and that emergence of resistance for that dose will arise in a specified percentage of patients. In other words, we are interested in quantitative predictions. Here, we calculated percentage accuracy as how close a prediction of the HFS-TB and Monte Carlo simulations of particular value of a dose, drug exposure value, or response rate was to what was observed later in the clinic. We propose a metric that can be integrated as a summation for predictions from many experiments and clinical studies, allowing metaanalysis. These results of this approach for the HFS-TB were presented by a Critical Path to TB Regimens workgroup to the Food and Drug Administration as part of a voluntary exploratory data submission, and to the European Medicines Agency for review and opinion.
METHODS

Literature Search
HFS-TB experiments that were published, or presented at international scientific meetings, between 1 January 2000 and 31 December 2012 were identified as described in accompanying publication [9] . The findings constituted the quantitative predictions.
Next, we performed a literature search to identify clinical studies that were published after the published predictions of HFS-TB experiments. To avoid hindsight bias, the time when clinical studies were published (defined as t 2 ) was set to be at least 6 months after the publication of the corresponding HFS-TB studies (defined as t 1 ), so that t 2 > t 1 + 6 months. Two members of the team (T. G., J. G. P.) searched PubMed, Embase, ISI Web of Science, and the Cochrane Libraries for clinical studies published from 1 January 2003, the year the HFS-TB was first introduced at Interscience Conference of Antimicrobial Agents and Chemotherapy, until 31 December 2012. Search terms with either isoniazid or rifampin or rifampicin or pyrazinamide or ethambutol or moxifloxacin or ciprofloxacin or linezolid AND tuberculosis were used and the results filtered to include only clinical trials. The drugs for the search string were chosen based on results from the literature search for the systematic analysis of HFS-TB experiments [9] . In addition, the team searched other literature sources via Inside Conferences, ClinicalTrials.gov, and Open Grey (System for Information on Grey Literature in Europe; http://www.opengrey.eu). Where conference abstracts were found, but a full study was published later in scientific journals, the full study was taken as the main reference (and thus final publication date reference may be after 31 December 2012). There was no exclusion of articles by language. Search findings by the first 2 researchers were then presented to the full group of investigators who examined the findings, and sought for further publications where they could be found.
Minimizing Bias and Quality of Evidence
To minimize bias and for reporting systematic reviews, we applied steps and criteria outlined by the Cochrane collaboration, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [10] , and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (http:// www.gradeworkinggroup.org/publications/JCE_series.htm). All publications of clinical studies retrieved were judged for quality of evidence in accordance with the scale described in Supplementary Table 1 . The score is based on both the GRADE criteria and those used by the Infectious Diseases Society of America-US Public Health Service Grading System for evidence-based medicine decision making [11] .
Calculation of Predictive Accuracy and Bias
For the HFS-TB experiments that predicted drug concentrations and/or exposures associated with either optimal efficacy or emergence of drug resistance, susceptibility breakpoints, or proportions of patients achieving a particular response, pairs of the HFS-TB ± Monte Carlo simulation vs human clinical data were examined. Both accuracy and bias were calculated and then summated. Error (E) was defined as the observed quantitative results in a clinical study (T) at t 2 , minus the HFS-TB predictive value (P) made at t 1 (where t 2 > t 1 + 6 months), or:
For a number of trials or experiments i of up to n, this takes the form of the mean absolute percentage error (MAPE), which is given by:
If the MAPE is the forecasting error (FE), the accuracy (A) is defined by:
Bias (B) is the tendency of a given DDT to overstate or understate the true or observed value. Bias was defined as:
Weighting accuracy and for bias for the clinical studies was based on the size of the population sample, divided by the quality-of-evidence score. For HFS-TB experiments, no true accuracy measure was assumed, reverting weighting to a fixedeffects model.
Predictive Accuracy and Bias of Base Model
Given the lack of a gold standard nonclinical DDT for tuberculosis with a defined and quantified predictive accuracy, the implications of a completely unreliable tool were explored. Assumptions of randomly generated pairs of quantitative prediction at t 1 vs clinically generated values at t 2 as the base model currently available for forecasting (ie, random guess) were evaluated. A random number generator was utilized to generate actual or true values and predict value pairs for 1000 experiments.
RESULTS
We identified 26 HFS-TB studies, including computer-aided clinical trial simulations based on Monte Carlo group of methods that utilized HFS-TB output, outlined in detail elsewhere [9] . From these, HFS-TB studies that predicted the drugs in our search criteria for clinical studies were chosen [5, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . There were 12 combination therapy HFS-TB studies, 10 monotherapy studies, and 4 studies based solely on Monte Carlo simulations that used prior published HFS-TB experimental output. We identified 20 clinical studies published after HFS-TB studies; the quality-of-evidence scores of these studies are shown in Table 1 . These clinical studies consisted of 2 types of output: qualitative or categorical outcomes, and quantitative data outcomes. Table 2 shows the predictions of the HFS-TB in tandem with Monte Carlo simulations at t 1 paired to the clinical studies that examined the qualitative output of PK/PD drivers of drug efficacy at t 2 . Table 2 also demonstrates that the optimal dosing schedules identified in the HFS-TB correlated well with the optimal dosing schedules identified in clinical studies. Table 3 is a summary of the predictive accuracy of the HFS-TB in regard to other qualitative outcomes for acquired drug resistance (ADR) and therapy failure. Some of the new hypotheses and proposals were contrary to accepted concepts in the field of tuberculosis therapeutics at that time. These include the role of adherence in preventing ADR, the role of pharmacokinetic variability in clinical outcomes, and the emerging role of efflux pumps in ADR, especially the antibiotic resistance arrow of time. The molecular sequence of events leading to acquisition of drug resistance is "the antibiotic resistance arrow of time," in which resistance emergence is a process rather than an endpoint [49] . These novel concepts have direct relevance in the design of new drug regimens and new dosing concepts that will minimize the emergence of drug resistance and therapy failure. For example, they de-emphasize the necessity to develop new drug combinations in fixed-dose formulations or rifamycins with long half-life.
The random or "total guesswork" model was demonstrated to be 100% accurate in 1.6% of experiments, whereas 6% were within 95% of the actual value (ie, error <5%). Mean accuracy (95% confidence interval [CI]) was 15.6% (8.7%-22.5%). The mean bias (B) was −0.1% (−2.5% to 2.2%). These results mean that even random guessing has a forecasting accuracy above 0% (even a broken clock is correct twice a day). This means that a truly value-added DDT would have to improve upon this accuracy rate of 15.6%, which may occur with chance, and be better than the upper 95% CI of 22.5%.
The literature search of clinical studies published after HFS-TB predictions at t 1 , identified 8 clinical studies at t 2 that Table 4 ). The nonweighted observed vs predicted values are shown in Figure 1 . When the accuracy was weighted using both the number of patients in the study, and quality-of-evidence score, the predictive accuracy was as shown in Table 4 . The 95% CI for predictive accuracy was 84.3%-99.9%. The bias was −13.7% to 6.2% and thus crossed zero. Thus, the HFS-TB was several-fold more accurate at forecasting clinical pharmacological parameters than the random or guessing baseline model, although the bias was similar. The primary reason that the estimate was only 94% was due to the minimum inhibitory concentration (MIC) breakpoints, which have a base 2 scale. An error of a 1-tube dilution, considered to be acceptable by clinical laboratory standards, results to an error of 50% when using MAPE.
DISCUSSION
First, we present a framework by which nonclinical DDTs can be evaluated for predictive accuracy of clinical outcomes. Quantified predictive accuracy of a given tool gives confidence to drug developers by defining a metric of translation to meaningful clinical outcome. This methodology could be employed to evaluate performance for many other DDTs, beyond tuberculosis and infectious diseases. Where predictive accuracy of a base model is known, these methods can be used to directly compare a new DDT to that standard for that field. These types of nonclinical models can be used, and evaluated for accuracy toward a specific context of use and application by regulatory bodies. Second, we demonstrate that the HFS-TB had good predictive accuracy. On the basis of this accuracy, the HFS-TB was MOXI and CIPRO standard doses have a biphasic kill pattern due to differences in concentrations associated with optimal microbial kill and those associated with suppression of ADR, which led to ADR arising between day 10 and 14 [5, 15] .
(i) Biphasic kill rate of Mycobacterium tuberculosis and emergence of ADR with >10 d of monotherapy with MOXI, levofloxacin, and CIPRO [32] . (ii) Biphasic kill of MOXI administered for ≥10 d [33] . CIPRO (and ofloxacin) used at standard doses with second-line agents in MDR-TB will lead to further ADR within 1-2 wk [15] .
Emergence of what was later termed XDR-TB when quinolones used with second-line drugs in MDR-TB [34, 35] . Efflux pump-derived multidrug resistance to monotherapy as an early event leading to high-level resistance chromosomal mutations; the "antibiotic resistance arrow of time" [21, 49] .
(i) Transcriptional profile of sequential sputum isolates in patients who were in the process of developing MDR-TB from initially susceptible isolates, despite short-course DOTS [39] . (ii) ii-iii. Demonstration that efflux pump inhibitors can reverse drug resistance in MDR-TB and XDR-TB clinical isolates [37, 38] .
ADR and most microbiological failure are not due to poor compliance [28] .
Meta-analysis of 10 prospective trials of patients on DOT (n = 8774) vs SAT (n = 3708): Incidence ratios for DOT vs SAT were 1.5% vs 1.7% for microbiological failure, 3.7% vs 2.3% for relapse, and 1.5% vs 0.9% for ADR [50] .
Drug resistance and therapy failure is driven by pharmacokinetic variability [28] .
(i) Meta-analysis of 13 randomized studies with 1631 rapid acetylators and 1751 slow acetylators. The rapid vs slow acetylator relative risk was 2.0 for microbiological failure and 2.0 for ADR, even in combination therapy [39] . (ii) Clinical cohort of 142 patients demonstrated poor long-term outcomes such as relapse and therapy failure, as well as 2-mo sputum conversion [40] .
Abbreviations: ADR, acquired drug resistance; CIPRO, ciprofloxacin; DOT, directly observed therapy; MDR-TB, multidrug-resistant tuberculosis (concurrent resistance to isoniazid and rifampin); MOXI, moxifloxacin; SAT, self-administered therapy; XDR-TB, multidrug-resistant tuberculosis plus resistance to a quinolone and an injectable antituberculosis drug.
proposed as a valuable tool for antituberculosis drug and drug regimen development. As a tractable dynamic nonclinical PK/ PD model, the HFS-TB model is expected to minimize the need for extensive dose-finding studies in animal models and clinical trials and thereby shorten the duration of tuberculosis drug development programs. Additionally, the use of HFS-TB may help better design animal efficacy studies and improve on designs of combination studies. When used early in the drug development cycle, information regarding optimal dose selection, dosing schedules, and potential combination therapies can be obtained. The model can also be used to optimize animal model studies and, in tandem with such in vivo models, be used for optimal dose and dose schedule selection. In appropriate circumstances, the need for dose-ranging study designs, which potentially expose some patients to suboptimal doses, might be avoided. In later-phase development, HFS-TB provides information to help identify the optimal doses and combinations for phase 2 and 3 studies, the proportion of patients expected to have maximal response, and the expected rates of acquired drug resistance. Additionally, the HFS-TB can be used in a postapproval setting to optimize currently used drug regimens (for both dose and dosing schedule) for drug-susceptible and drugresistant tuberculosis. Therefore, the results obtained by the HFS-TB are expected to support trial design for phase 1, 2, 3, and 4 clinical trials. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) rendered a positive qualification opinion for HFS-TB to be used in antituberculosis drug development programs as an additional and complementary tool to existing methodologies to inform dose and regimen selection, including combinations of ≥2 drugs, to maximize bactericidal effects and minimize emergence of drug resistance. Thus, HFS-TB can be used in regulatory submissions throughout the drug development process for more informed design and interpretation of phase 1, 2, and 3 clinical studies. On the other hand, the qualification opinion does not mandate the use of the HFS-TB or exclude the use of alternative methods.
There are limitations to our study. First, as additional clinical studies are performed and identified, the predictive accuracy may change. Therefore, review and analyses of these new studies should be reported regularly. Second, in our study, a number of different quantitative outputs were combined, and as more studies are performed, the predictive accuracy for each output (eg, dose vs optimal exposure vs susceptibility breakpoint) can be delineated by leveraging those additional incoming data. Third, data on meningitis utilized area under the concentration time curve to minimum inhibitory concentration ratio exposures identified for the quinolone class (based on contributions of different individual quinolones). In addition, the maximal exposure value was read of published graphs. Thus, it could be argued that the moxifloxacin exposure examined in the predictive accuracy should not be included in the analysis. However, the study was weighted at 12%, and its exclusion would simply change the predictive accuracy from 94% to 93%. Nevertheless, despite these limitations, there is sufficient data to identify the high predictive accuracy of the HFS-TB.
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